

Multiple System Atrophy

[View the current Multiple System Atrophy InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Multiple_System_Atrophy.html) - Regularly Updated.

Recent Publications on Multiple System Atrophy:



- [Selective nuclear shrinkage of oligodendrocytes lacking glial cytoplasmic inclusions in multiple system atrophy: a 3-dimensional volumetric study.](#)
Glial cytoplasmic inclusions (GCIs) are a pathologic hallmark of multiple... 18th November, 2009
Department of Neurology, Tokyo Metropolitan Institute for Neuroscience,- J Neuropathol Exp Neurol. 2009 Oct;68(10):1084-91. ([DOI Direct Link](#))
- [Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.](#)
The reactive changes in different types of astrocytes were analyzed in... 18th November, 2009
Prince of Wales Medical Research Institute and the University of New South- J Neuropathol Exp Neurol. 2009 Oct;68(10):1073-83. ([DOI Direct Link](#))
- [Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from pd?](#)
BACKGROUND: The diagnosis of multiple system atrophy (MSA) remains... 18th November, 2009
Movement Disorders Section, Raul Carrea Institute for Neurological- Int J Neurosci. 2009;119(12):2257-61.
- [Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivatives and ferric iron.](#)
Intracellular alpha-synuclein (alpha-syn) aggregates are the pathological... 17th November, 2009
Center for Neuropathology and Prion Research,- Biochem Biophys Res Commun. 2009 Nov 12. ([DOI Direct Link](#))
- [Multiple system atrophy: an update.](#)
Multiple system atrophy (MSA) is a sporadic and rapidly progressive... 17th November, 2009
Division of Clinical Neurobiology, Department of Neurology, Medical- Lancet Neurol. 2009 Dec;8(12):1172-8. ([DOI Direct Link](#))
- [Ocular-jaw synkinesia in normal, Parkinson's disease, and multiple system atrophy subjects: Clinical and electrophysiological findings.](#)
OBJECTIVE: We occasionally observe cranial synkinesias that involve a... 13th November, 2009
Hospital Arnau de Vilanova, Department of Neurology, Lleida, Spain.- Clin Neurophysiol. 2009 Nov 9. ([DOI Direct Link](#))
- [Brain {alpha}-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.](#)
alpha-Synuclein is a major component of Lewy bodies and glial cytoplasmic... 12th November, 2009
1 Movement Disorders Research Laboratory, Centre for Addiction and Mental- Brain. 2009 Nov 10. (

[DOI Direct Link](#))

- [Usefulness of 3D-PRESTO imaging in evaluating putaminal abnormality in parkinsonian variant of multiple system atrophy.](#)
*INTRODUCTION: Principles of echo shifting with a train of observations...*7th November, 2009
Department of Radiology, Nagoya City University Graduate School of Medical- Neuroradiology. 2009 Nov 6. ([DOI Direct Link](#))
- [MR imaging in multiple system atrophy: Its role in "splitting" parkinsonism.](#)
*INTRODUCTION: Principles of echo shifting with a train of observations...*7th November, 2009
Department of Neurology, National Institute of Mental Health and- Ann Indian Acad Neurol. 2008 Oct;11(4):257-8. ([DOI Direct Link](#))
- [An autopsy report on multiple system atrophy diagnosed immunohistochemically despite severe ischaemic damage: a new approach for investigation of medical practice associated deaths in Japan.](#)
*A 60-year old man with a 10-year history of multiple system atrophy (MSA)...*29th October, 2009
Department of Forensic Medicine, Graduate School of Medicine, The- J Clin Pathol. 2009 Nov;62(11):1029-33. ([DOI Direct Link](#))
- [Neuromuscular junctions of the posterior cricoarytenoid muscle in multiple system atrophy: a case study.](#)
*CONCLUSION: The present study showed a variety of stages of neurogenic...*24th October, 2009
Department of Otolaryngology, Tokyo Women's Medical University, Tokyo,- Acta Otolaryngol Suppl. 2009 Jun;(562):115-9.
- [An exploration of ocular fixation in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.](#)
*Since the basal ganglia are thought to have a role in controlling ocular...*23rd October, 2009
Northern Ireland Regional Medical Physics Agency, Royal Victoria Hospital,- J Neurol. 2009 Oct 22. ([DOI Direct Link](#))
- [A validation exercise on the new consensus criteria for multiple system atrophy.](#)
*The revised (new) consensus clinical diagnostic criteria for multiple...*22nd October, 2009
National Hospital for Neurology and Neurosurgery, Queen Square, London,- Mov Disord. 2009 Oct 20;24(15):2272-2276. ([DOI Direct Link](#))
- [Concomitant progressive supranuclear palsy and multiple system atrophy: more than a simple twist of fate?](#)
*Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are...*20th October, 2009
Reta Lila Weston Institute for Neurological Studies, UCL Institute of- Neurosci Lett. 2009 Dec 31;467(3):208-11. Epub 2009 Oct 14. ([DOI Direct Link](#))
- [Usefulness of tilt-induced heart rate changes in the differential diagnosis of vasovagal syncope and chronic autonomic failure.](#)
*OBJECTIVE: To determine whether the heart rate changes during tilt table...*17th October, 2009
Dysautonomia Center, Department of Neurology, NYU School of Medicine, New- Clin Auton Res. 2009 Dec;19(6):375-80. ([DOI Direct Link](#))

Multiple System Atrophy Patents:



- 7491501- [Methods for identifying modulators of intracellular aggregate formation](#)
- 7524489- [Regeneration and repair of neural tissue using postpartum-derived cells](#)

- 7524640- [Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia](#)
- 7531572- [Acyloxyalkyl carbamate prodrugs of .alpha.-amino acids, methods of synthesis and use](#)
- 7531713- [Assay for toxin induced neuronal degeneration and viability in C. elegans](#)
- 7534765- [Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin](#)
- 7534918- [Histone deacetylase inhibitors](#)
- 7538114- [Glycine transporter-1 inhibitors](#)
- 7544694- [Substituted diaza-spiro-\[5.5\]-undecane derivatives and their use as neurokinin antagonists](#)
- 7544695- [Spirocyclic compounds](#)
- 7547781- [Quinazoline based EGFR inhibitors containing a zinc binding moiety](#)
- 7521481- [Methods of preventing, treating and diagnosing disorders of protein aggregation](#)
- 7517864- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7514583- [Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease](#)
- 7495112- [Isoindoline compounds and methods of making and using the same](#)
- 7501418- [Fused heterocyclic isoxazoline derivatives and their use as anti-depressants](#)
- 7504247- [2-O sulfatase compositions and methods of degradation therewith](#)
- 7507570- [Recombinant chondroitinase ABC I and uses thereof](#)
- 7507828- [Histone deacetylase inhibitors and methods of use thereof](#)
- 7507858- [Histone deacetylase inhibitors](#)
- 7511072- [7-amido-isoinidolyl compounds and methods of its use](#)
- 7514099- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7514424- [Substituted 4-\(4-piperidin-4-yl-piperazin-1-yl\)-azepane derivatives and their use as neurokinin antagonists](#)
- 7514445- [Heteroaryl amines as glycogen synthase kinase 3.beta. inhibitors \(GSK3 inhibitors\)](#)
- 7550648- [Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau protein](#)
- 7553639- [Alpha-synuclein kinase](#)
- 7595306- [Method of treating neurodegenerative disease](#)
- 7598256- [Pyrrolo \[2,3-d\] pyrimidine and their use as purinergic receptor antagonists](#)
- 7601876- [Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis](#)
- 7604993- [Combined regulation of neural cell production](#)
- 7605133- [Isolated peptides to treat alpha-synuclein diseases](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7612056- [Substituted diaza-spiro-\[4.5\]-decane derivatives and their use as neurokinin antagonists](#)
- 7618622- [Treatment of Parkinson's disease and related disorders using postpartum derived cells](#)
- 7618634- [Neurotoxic oligomers](#)
- 7618988- [Use of substituted aminomethyl chromans](#)
- 7595159- [Prediction of Parkinson's disease using gene expression levels of peripheral blood samples](#)
- 7592152- [Chondroitinase ABC I and methods of analyzing therewith](#)
- 7589097- [Triazol\[4,5-d\] pyrimidine derivatives and their use as purinergic receptor antagonists](#)
- 7553950- [Chondroitinase ABC I polynucleotides](#)
- 7554003- [Invertebrate animal model with neurodegenerative phenotype for screening and testing substances](#)
- 7560276- [Soft tissue repair and regeneration using postpartum-derived cells](#)
- 7560458- [Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors](#)
- 7561923- [Method and apparatus for controlling autonomic balance using neural stimulation](#)
- 7572786- [Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists](#)
- 7572792- [Azetidine glycine transporter inhibitors](#)
- 7576073- [Combined therapy for the treatment of parkinson's disease](#)

- 7576080- [Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors](#)
- 7576083- [Morpholinyl piperidine glycine transporter inhibitors](#)
- 7619091- [8-hydroxy quinoline derivatives](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

